Aeglea Biotherapeutics (AGLE) Receives a Buy from Needham

In a report released today, Chad Messer from Needham reiterated a Buy rating on Aeglea Biotherapeutics (AGLE), with a price target of $14.00. The company’s shares closed last Wednesday at $5.20.

According to, Messer is a 4-star analyst with an average return of 4.4% and a 38.3% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aeglea Biotherapeutics with a $20.00 average price target, implying a 296.0% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.11 and a one-year low of $3.50. Currently, Aeglea Biotherapeutics has an average volume of 64.88K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts